Cyclophosphamide (Cyclophosphamide) - Disability - Suspected Cause - Side Effect Reports

Possible Cyclophosphamide side effects in female

Reported by a physician from Canada on 2012-08-13

Patient: female

Reactions: Oral Herpes

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisolone
    Dosage: dose of last drug taken:100mg, date of recent dose taken prior to onset of ae:17/jun/2012
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Vincristine
    Dosage: route:intravenous push, dose of last drug taken:2mg, date of last dose taken prior to onset of ae:13
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Doxorubicin Hydrochloride
    Dosage: dose of last drug taken:91mg, date of last dose taken prior to onset of ae:13/jun/2012
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Mabthera
    Dosage: volume of last drug taken:343.5ml, dose concentration of last drug taken:1.99mg/ml, date of last do
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Cyclophosphamide
    Dosage: dose of last drug taken:1370mg, date of last dose taken prior to onset of ae:13/jun/2012
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Other drugs received by patient: Colace; Polyethylene Glycol; Tramadol Hydrochloride and Acetaminophen; Senokot; Valacyclovir Hydrochloride; Codeine; Benzydamine; Naproxen; Morphine; Preparation H Cream; Lidocaine; Valacyclovir Hydrochloride; Ranitidine; YAZ; Morphine; Pantoprazole; Acetaminophen; Diphenhydramine Hydrochloride; Suppository (Unk Ingredients)

Possible Cyclophosphamide side effects in male

Reported by a physician from Japan on 2012-08-09

Patient: male, weighing 57.0 kg (125.4 pounds)

Reactions: Cytomegalovirus Hepatitis, Cytomegalovirus Enterocolitis, Cytomegalovirus Chorioretinitis, Pancytopenia

Adverse event resulted in: life threatening event, hospitalization, disablity

Drug(s) suspected as cause:
Cyclosporine
    Administration route: Oral
    Indication: Histiocytosis Haematophagic
    Start date: 2011-09-26

Rituximab
    Indication: Histiocytosis Haematophagic
    Start date: 2011-04-13

Rituximab
    Dosage: cycle 3 % 4
    Indication: B-Cell Lymphoma
    Start date: 2011-05-25

Vincristine Sulfate
    Indication: Histiocytosis Haematophagic

Vincristine Sulfate
    Dosage: 2 milligram daily;
    Indication: B-Cell Lymphoma
    Start date: 2011-09-27

Prednisolone
    Dosage: 60 milligram daily;
    Administration route: Oral
    Indication: B-Cell Lymphoma
    Start date: 2011-09-09
    End date: 2011-10-17

Treanda
    Indication: B-Cell Lymphoma
    Start date: 2011-04-13

Cyclophosphamide
    Indication: Histiocytosis Haematophagic

Prednisolone
    Indication: Histiocytosis Haematophagic

Etoposide
    Indication: Histiocytosis Haematophagic
    Start date: 2011-09-13

Cyclophosphamide
    Dosage: 1200 milligram daily;
    Indication: B-Cell Lymphoma
    Start date: 2011-09-27
    End date: 2011-10-17

Doxorubicin HCL
    Indication: Histiocytosis Haematophagic
    Start date: 2011-09-27

Other drugs received by patient: Pirarubicin Hydrochloride

Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-01

Patient: female

Reactions: Gait Disturbance, Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Vincristine Sulfate
    Indication: Burkitt's Lymphoma

Doxorubicin Hydrochloride
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Indication: Burkitt's Lymphoma

(Mabthera)
    Dosage: intravenous drip
    Indication: Burkitt's Lymphoma

Prednisone
    Indication: Burkitt's Lymphoma

Possible Cyclophosphamide side effects in 33 year old female

Reported by a pharmacist from Japan on 2012-07-27

Patient: 33 year old female

Reactions: Cystitis Haemorrhagic, Shock Haemorrhagic

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2008-09-01
    End date: 2011-08-01

Halaven
    Indication: Breast Cancer
    Start date: 2011-09-12
    End date: 2011-10-31

Possible Cyclophosphamide side effects in female

Reported by a physician from United Kingdom on 2012-07-27

Patient: female

Reactions: Abasia, Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Mabthera
    Dosage: unk
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Doxorubicin HCL
    Dosage: unk

Prednisone TAB
    Dosage: unk
    Indication: Product Used FOR Unknown Indication

Cyclophosphamide
    Dosage: unk

Possible Cyclophosphamide side effects in female

Reported by a lawyer from France on 2012-07-27

Patient: female

Reactions: Cardiomyopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 6 cycles
    Indication: Breast Cancer
    Start date: 2004-07-15
    End date: 2004-11-05

Fluorouracil
    Dosage: 6 cycles
    Indication: Breast Cancer
    Start date: 2004-07-15
    End date: 2004-11-05

Epirubicin Hydrochloride
    Dosage: 6 cycles
    Indication: Breast Cancer
    Start date: 2004-07-15
    End date: 2004-11-05

Other drugs received by patient: Levothyroxine Sodium; Tamoxifen Citrate; Levothyroxine Sodium; Lipanthyl 160; Aromasin

Possible Cyclophosphamide side effects in 42 year old female

Reported by a physician from United Kingdom on 2012-07-27

Patient: 42 year old female, weighing 91.0 kg (200.2 pounds)

Reactions: Sinus Headache

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide

Possible Cyclophosphamide side effects in female

Reported by a physician from United Kingdom on 2012-07-27

Patient: female

Reactions: Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Mabthera
    Indication: Burkitt's Lymphoma

Doxorubicin Hydrochloride
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Burkitt's Lymphoma

Prednisone
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Indication: Burkitt's Lymphoma

Possible Cyclophosphamide side effects in female

Reported by a physician from United Kingdom on 2012-07-23

Patient: female

Reactions: Abasia, Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisone

Doxorubicin Hydrochloride

Vincristine

Mabthera
    Indication: Burkitt's Lymphoma

Cyclophosphamide

Possible Cyclophosphamide side effects in 65 year old male

Reported by a health professional (non-physician/pharmacist) from Germany on 2012-07-19

Patient: 65 year old male, weighing 82.0 kg (180.4 pounds)

Reactions: Arrhythmia Supraventricular, Incontinence, JC Virus Infection, Hemiparesis, Somnolence, Progressive Multifocal Leukoencephalopathy, Blindness, Demyelination

Adverse event resulted in: death, hospitalization, disablity

Drug(s) suspected as cause:
Rituximab (Rituximab)
    Dosage: 500 mg/m^2; day 14
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Dosage: 150 mg/m^2; day 1-3
    Indication: Chronic Lymphocytic Leukaemia

Fludarabine Phosphate
    Dosage: 20 mg/m^2; day 1-3
    Indication: Chronic Lymphocytic Leukaemia

Other drugs received by patient: Chlorambucil; Flecainide Acetate

Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-07-17

Patient: female

Reactions: Palmar-Plantar Erythrodysaesthesia Syndrome, Paraesthesia

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Start date: 2012-05-24

Cyclophosphamide
    Start date: 2012-05-10

Vincristine
    Start date: 2012-05-10

Cyclophosphamide
    Start date: 2012-05-24
    End date: 2012-05-24

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-05-10

Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-05-24

Doxorubicin HCL
    Start date: 2012-05-10

Vincristine
    Start date: 2012-05-24
    End date: 2012-05-24

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26
    End date: 2012-05-24

Other drugs received by patient: Rituximab; Prednisone; Prednisone; Prednisone; Rituximab; Rituximab

Possible Cyclophosphamide side effects in female

Reported by a physician from United Kingdom on 2012-07-16

Patient: female

Reactions: Abasia, Myelopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: Product Used FOR Unknown Indication

Vincristine
    Indication: Product Used FOR Unknown Indication

Mabthera
    Indication: Burkitt's Lymphoma

Prednisone
    Indication: Product Used FOR Unknown Indication

Cyclophosphamide
    Indication: Product Used FOR Unknown Indication

Possible Cyclophosphamide side effects in 28 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-11

Patient: 28 year old female

Reactions: Streptococcal Bacteraemia, Vomiting, Nausea, Peripheral Sensorimotor Neuropathy, Carbon Monoxide Diffusing Capacity Decreased, Pancytopenia, Febrile Neutropenia, Hypoaesthesia, Paraesthesia, Gait Disturbance, Coordination Abnormal, Renal Failure Acute

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Cisplatin
    Dosage: 45 mg/m2, unk

Bleomycin Sulfate
    Dosage: 15 units/m2 over 24h on day2

Etoposide
    Dosage: 200 mg/m2, over 2h on day3
    Indication: Ovarian Cancer

Cyclophosphamide
    Dosage: 750 mg/m2, unk

Cisplatin
    Dosage: 90 mg/m2, over 4h on day1
    Indication: Ovarian Cancer

Doxorubicin HCL
    Dosage: 30 mg/m2, unk

Etoposide
    Dosage: 100 mg/m2, unk

Cyclophosphamide
    Dosage: 1000 mg/m2, over 60min on day 2
    Indication: Ovarian Cancer

Doxorubicin HCL
    Dosage: 45 mg/m2, over 30min on day3
    Indication: Ovarian Cancer

Vinblastine
    Dosage: 6 mg/m2, over 30 minutes on day 1
    Indication: Ovarian Cancer

Other drugs received by patient: Pegfilgrastim

Possible Cyclophosphamide side effects in female

Reported by a physician from Canada on 2012-07-10

Patient: female

Reactions: Stomatitis, LIP Ulceration

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisolone
    Dosage: dose of last drug taken:100mg, date of recent dose taken prior to onset of ae:17/jun/2012
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Cyclophosphamide
    Dosage: dose of last drug taken:1370mg, date of last dose taken prior to onset of ae:13/jun/2012
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Vincristine Sulfate
    Dosage: route:intravenous push, dose of last drug taken:2mg, date of last dose taken prior to onset of ae:13
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Mabthera
    Dosage: volume of last drug taken:343.5ml, dose concentration of last drug taken:1.99mg/ml, date of last do
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Doxorubicin Hydrochloride
    Dosage: dose of last drug taken:91mg, date of last dose taken prior to onset of ae:13/jun/2012
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2012-04-10

Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-07-03

Patient: female

Reactions: Palmar-Plantar Erythrodysaesthesia Syndrome

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2012-05-10

Cyclophosphamide
    Start date: 2012-05-24

Doxorubicin HCL
    Start date: 2012-05-24

Vincristine
    Start date: 2012-05-10

Vincristine
    Start date: 2012-05-24

Rituxan
    Start date: 2012-05-24

Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Doxorubicin HCL
    Start date: 2012-05-10

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Rituxan
    Start date: 2012-05-10

Prednisone
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Rituxan
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Prednisone
    Start date: 2012-05-10

Doxorubicin HCL
    Indication: B-Cell Lymphoma
    Start date: 2012-04-26

Prednisone
    Start date: 2012-05-24

Possible Cyclophosphamide side effects in 62 year old female

Reported by a health professional (non-physician/pharmacist) from Switzerland on 2012-06-30

Patient: 62 year old female

Reactions: Off Label Use, JC Virus Infection, Progressive Multifocal Leukoencephalopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prednisone TAB
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Etoposide
    Indication: Hodgkin's Disease Recurrent

Procarbazine Hydrochloride
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Doxorubicin HCL
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Vincristine
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Cyclophosphamide
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Bleomycin Sulfate
    Dosage: 8 cycles
    Indication: Hodgkin's Disease Recurrent

Possible Cyclophosphamide side effects in 58 year old female

Reported by a health professional (non-physician/pharmacist) from France on 2012-06-29

Patient: 58 year old female

Reactions: Cardiac Failure, Mitral Valve Incompetence, Systolic Dysfunction

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500 mg/m2, cyclic
    Indication: Breast Cancer
    Start date: 2002-02-25
    End date: 2002-06-17

Fluorouracil
    Dosage: 500 mg/m2, cyclic
    Indication: Breast Cancer
    Start date: 2002-02-25
    End date: 2002-06-17

Epirubicin Hydrochloride
    Dosage: 100 mg/m2, cyclic
    Indication: Breast Cancer
    Start date: 2002-02-25
    End date: 2002-06-17

Possible Cyclophosphamide side effects in 28 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-29

Patient: 28 year old female

Reactions: Streptococcal Bacteraemia, Vomiting, Nausea, Peripheral Sensorimotor Neuropathy, Carbon Monoxide Diffusing Capacity Decreased, Pancytopenia, Febrile Neutropenia, Hypoaesthesia, Paraesthesia, Coordination Abnormal, Gait Disturbance, Renal Failure Acute

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Cisplatin
    Dosage: 90 mg/m2 over 4h on day1
    Indication: Ovarian Cancer

Cisplatin
    Dosage: 45 mg/m 2

Etoposide
    Dosage: 200 mg/m2 over 2h on day3
    Indication: Ovarian Cancer

Cyclophosphamide
    Dosage: 1000 mg/m2 over 60min on day 2
    Indication: Ovarian Cancer

Bleomycin
    Dosage: 15 units/m2 over 24h on day2

Doxorubicin HCL
    Dosage: 45 mg/m2 over 30min on day3
    Indication: Ovarian Cancer

Etoposide
    Dosage: 100 mg/m 2

Cyclophosphamide
    Dosage: 750 mg/m 2

Doxorubicin HCL
    Dosage: 30 mg/m 2

Vinblastine
    Dosage: 6mg/m2 over 30min on day1
    Indication: Ovarian Cancer

Other drugs received by patient: Pegfilgrastim

Possible Cyclophosphamide side effects in male

Reported by a physician from France on 2012-06-27

Patient: male, weighing 103.0 kg (226.6 pounds)

Reactions: Cerebral Ischaemia

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Plavix
    Administration route: Oral
    Start date: 2011-04-28

Cyclophosphamide
    Start date: 2011-06-23
    End date: 2011-08-22

Fludarabine Phosphate
    Start date: 2011-06-23
    End date: 2011-08-22

NO Drug Administered (Rituximab)
    Indication: Chronic Lymphocytic Leukaemia

Other drugs received by patient: Aspirin; Phenoxymethyl Penicillin; Nitroglycerin; Novorapid; Digoxin; Nebivolol HCL; Lantus; Pentoxifylline; Atorvastatin; Lercanidipine; Lantus; Nebivolol HCL; Amaryl

Possible Cyclophosphamide side effects in female

Reported by a lawyer from France on 2012-06-22

Patient: female

Reactions: Cardiomyopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 6 cycles
    Indication: Breast Cancer
    Start date: 2004-07-15

Fluorouracil
    Dosage: 6 cycles
    Indication: Breast Cancer
    Start date: 2004-07-15

Epirubicin Hydrochloride
    Dosage: 6 cycles
    Indication: Breast Cancer
    Start date: 2004-07-15

Other drugs received by patient: Levothyroxine Sodium

Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-06-21

Patient: female

Reactions: Cardiac Failure, Mitral Valve Incompetence, Systolic Dysfunction

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2002-02-25
    End date: 2002-06-17

Fluorouracil
    Start date: 2002-02-25
    End date: 2002-06-17

Epirubicin Hydrochloride
    Start date: 2002-02-25
    End date: 2002-06-17

Possible Cyclophosphamide side effects in female

Reported by a individual with unspecified qualification from Denmark on 2012-06-15

Patient: female

Reactions: Thrombosis, Pain in Extremity, Thrombectomy, LEG Amputation

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Epirubicin
    Indication: Breast Cancer
    Start date: 2010-12-07

Cyclophosphamide
    Indication: Breast Cancer
    Start date: 2010-12-07

Taxotere
    Indication: Breast Cancer
    Start date: 2010-12-07

Other drugs received by patient: Clemastine Fumarate

Possible Cyclophosphamide side effects in female

Reported by a physician from Finland on 2012-05-31

Patient: female

Reactions: Progressive Multifocal Leukoencephalopathy

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Mabthera
    Dosage: frequency: two infusions
    Indication: Lupus Vasculitis
    Start date: 2009-11-11
    End date: 2009-12-29

Cyclophosphamide
    Dosage: six 1000 mg cycles
    Indication: Lupus Vasculitis
    Start date: 2009-05-26
    End date: 2009-10-21

Other drugs received by patient: Cortisone Acetate

Possible Cyclophosphamide side effects in 35 year old male

Reported by a physician from Israel on 2012-05-29

Patient: 35 year old male

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 25 mg/m2, m2for 2 cycles of standard beacopp
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2, for 2 cycles of standard beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2for 2 cycles of standard beacopp
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 600 mg/m2, for 4 cycles of escalated beacopp

Vincristine
    Dosage: 1.4 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Procarbazine
    Dosage: 700 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 1250 mg/m2 for 4 cycles of escalated beacopp

Bleomycin
    Dosage: 10 mg/m2, for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Prednisone TAB
    Dosage: 280 mg/m2,for all 6 cycles of beacopp
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 35 mg/m2, for 4 cycles of escalated beacopp

Possible Cyclophosphamide side effects in 46 year old female

Reported by a physician from Israel on 2012-05-29

Patient: 46 year old female

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Etoposide
    Dosage: 300 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Prednisone TAB
    Dosage: 280 mg/m2, for 6 cycles

Bleomycin Sulfate
    Dosage: 10 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Procarbazine
    Dosage: 700 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Possible Cyclophosphamide side effects in 45 year old female

Reported by a physician from Israel on 2012-05-25

Patient: 45 year old female

Reactions: Respiratory Disorder

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 25 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 300 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Bleomycin
    Dosage: 10 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: 650 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 700 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Prednisone TAB
    Dosage: 280 mg/m2, for 6 cycles
    Indication: Hodgkin's Disease

Possible Cyclophosphamide side effects in female

Reported by a physician from United States on 2012-05-25

Patient: female

Reactions: Lung Consolidation, Osteonecrosis, Joint Range of Motion Decreased, Arthralgia, Limb Asymmetry, Gait Disturbance

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Cytarabine
    Dosage: intrathecal
    Indication: Acute Lymphocytic Leukaemia

Daunorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Indication: Acute Lymphocytic Leukaemia

Vincristine Sulfate
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: intrathecal
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: intrathecal
    Indication: Acute Lymphocytic Leukaemia

Oncaspar
    Indication: Acute Lymphocytic Leukaemia

Thioguanine
    Indication: Acute Lymphocytic Leukaemia

Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-05-24

Patient: female

Reactions: Paraesthesia

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Start date: 2010-05-20
    End date: 2010-08-12

Vincristine
    Start date: 2010-09-02
    End date: 2010-10-14

Cyclophosphamide
    Start date: 2010-05-20
    End date: 2010-08-12

Cyclophosphamide
    Start date: 2010-09-02
    End date: 2010-10-14

Doxorubicin HCL
    Start date: 2010-09-02
    End date: 2010-10-14

Vincristine
    Start date: 2010-05-20
    End date: 2010-08-12

Other drugs received by patient: Prednisone TAB; Prednisone TAB

Possible Cyclophosphamide side effects in male

Reported by a physician from France on 2012-05-23

Patient: male, weighing 68.0 kg (149.6 pounds)

Reactions: Complications of Transplanted Kidney, Wound Dehiscence, Malnutrition, Bronchial Obstruction, Anastomotic Haemorrhage, Renal Impairment, Unevaluable Event, Culture Wound Positive, Thrombocytopenia, Escherichia Sepsis

Adverse event resulted in: death, life threatening event, hospitalization, disablity

Drug(s) suspected as cause:
Esomeprazole Magnesium
    Start date: 2011-01-16
    End date: 2011-02-01

Prednisone TAB
    Administration route: Oral
    Indication: Transplant Rejection

Cyclosporine

Everolimus
    Indication: Product Used FOR Unknown Indication
    Start date: 2011-02-02
    End date: 2011-02-09

Cellcept
    Dosage: permanently discontinued. date of last dose prior to sae: 08 march 2011.
    Administration route: Oral
    Start date: 2011-03-01
    End date: 2011-03-08

Cellcept
    Dosage: frequency: everyday. temporarily interrupted
    Administration route: Oral
    Indication: Transplant Rejection
    Start date: 2011-01-15
    End date: 2011-02-09

Prednisone TAB
    Dosage: date of last dose prior to sae: 16 march 2011.
    Administration route: Oral

Cyclophosphamide
    Administration route: Oral
    Indication: Transplant Rejection
    Start date: 2011-01-17
    End date: 2011-02-01

Methylprednisolone and Methylprednisolone
    Indication: Transplant Rejection
    Start date: 2011-01-15
    End date: 2011-01-15

Basiliximab
    Indication: Transplant Rejection
    Start date: 2011-01-15
    End date: 2011-01-15

Valcyte
    Dosage: twice a week
    Start date: 2011-01-29
    End date: 2011-02-01

Cyclosporine

Sulfamethoxazole and Trimethoprim
    Start date: 2011-01-24
    End date: 2011-02-01

Ranitidine HCL
    Start date: 2011-02-02
    End date: 2011-02-09

Other drugs received by patient: Adancor; Amlodipine Besylate; Insulatard NPH Human; Econazole Nitrate; Potassium Chloride; Adancor; Imodium; Alfuzosin HCL; Calcidia; Aspirin; Mirtazapine; Calcidia; Lasix; Eprex; Nitroderm; Potassium Chloride; Amoxicillin; Lasix; Sodium Bicarbonate; Aluminum Hydroxide and Magnesium Trisilicate

Possible Cyclophosphamide side effects in female

Reported by a individual with unspecified qualification from Japan on 2012-05-23

Patient: female

Reactions: Uterine Cancer, Urinary Tract Infection, Anaemia, Meningitis Bacterial, Leukoencephalopathy, Liver Disorder

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Xeloda
    Administration route: Oral
    Indication: Breast Cancer Metastatic
    Start date: 2007-08-01
    End date: 2010-12-12

Cefpirome Sulfate
    Indication: Product Used FOR Unknown Indication
    Start date: 2010-12-13
    End date: 2010-12-20

Cyclophosphamide
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    Start date: 2010-02-01
    End date: 2010-12-12

Cefpirome Sulfate
    Administration route: Oral
    End date: 2010-12-12

Other drugs received by patient: Mucosta; Tocopherol Concentrate CAP; Celestamine TAB; Meloxicam; Hirudoid; Cyclophosphamide; Neurovitan (Ukraine); Atines